Study identification

PURI

https://redirect.ema.europa.eu/resource/104140

EU PAS number

EUPAS104139

Study ID

104140

Official title and acronym

Impact of biologic initiation on steroid burden and new-onset of potentially OCS-related outcomes in patients with severe asthma (SOLAR)

DARWIN EU® study

No

Study countries

Argentina
Australia
Bulgaria
Canada
Colombia
Denmark
Greece
Hungary
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Poland
Portugal
Saudi Arabia
Singapore
Spain
Taiwan
United Arab Emirates
United Kingdom
United States

Study status

Planned
Research institution and networks

Institutions

Contact details

David Price

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:

Data collection

Planned:

Date of interim report, if expected

Planned:

Date of final study report

Planned:
Sources of funding
Other
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, OPRI Pte Ltd
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable